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Abstract
In this study we evaluated the effects of the CB1/CB2 cannabinoid receptor agonist CP55, 940 (CP) on antigen-induced asthma-like reac-
tion in sensitized guinea pigs and we tested the ability of the specific CB2 receptor antagonist SR144528 (SR) and CB1 receptor antag-
onist AM251 (AM) to interfere with the effects of CP. Ovalbumin-sensitized guinea pigs placed in a respiratory chamber were challenged
with the antigen given by aerosol. CP (0.4 mg/kg b.wt.) was given i.p. 3 hrs before ovalbumin challenge. Sixty minutes before CP admin-
istration, some animals were treated i.p. with either AM, or SR, or both (0.1 mg/kg b.wt.). Respiratory parameters were recorded and
quantified. Lung tissue specimens were then taken for histopathological and morphometric analyses and for eosinophilic major basic
protein immunohistochemistry. Moreover, myeloperoxidase activity, 8-hydroxy-2-deoxyguanosine, cyclic adenosine monophosphate
(cAMP) and guanosine monophosphate (cGMP) levels, and CB1 and CB2 receptor protein expression by Western blotting were evaluat-
ed in lung tissue extracts. In the bronchoalveolar lavage fluid, the levels of prostaglandin D2 and tumour necrosis factor- TNF- were
measured. Ovalbumin challenge caused marked abnormalities in the respiratory, morphological and biochemical parameters assayed.
Treatment with CP significantly reduced these abnormalities. Pre-treatment with SR, AM or both reverted the protective effects of CP,
indicating that both CB1 and CB2 receptors are involved in lung protection. The noted treatments did not change the expression of
cannabinoid receptor proteins, as shown by Western blotting. These findings suggest that targeting cannabinoid receptors could be a
novel preventative therapeutic strategy in asthmatic patients.
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Introduction
Asthma is a chronic inflammatory disease of the airways charac-
terized by eosinophilia, increased vascular permeability in the
bronchial mucosa, mucus hypersecretion and airway hyperre-
sponsiveness. The prevalence of asthma has increased dramati-
cally over the past decades and currently affects about 10% of the
population in developed countries [1]. Although there is a general
consensus about the use of corticosteroids and bronchodilators
as main therapeutic measures for the prevention and management
of asthma, the identification and development of promising new
substances with anti-asthmatic effects that can flank and co-oper-
ate with the above drugs is a fertile field for basic and clinical
research because of its primary medical interest.
Recently, claims have been made for the beneficial effects of
cannabis and cannabinoids, the active components of Cannabis
sativa. This plant has a long history as a drug source. Over the cen-
turies, it has been used for many purposes, including the treatment
of asthma [2]. Early studies have indicated that cannabinoids have
bronchodilatory effects in asthmatic patients when administered
either orally or by aerosol [3, 4]. Moreover, cannabinoids also have
anti-inflammatory effects [5, 6] and have been recently used as
novel therapeutic tools in immune-mediated diseases, such as
multiple sclerosis [7], rheumatoid arthritis [8] and diabetes [9]. 
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In murine models of ovalbumin-induced allergic airway response,
cannabinoids have shown inhibitory effects on T cell cytokine
expression, serum IgE levels and mucus overproduction [10].
Cannabinoids bind to specific G-protein-coupled receptors [11,
12]. To date, two cannabinoid receptors, termed CB1 and CB2, have
been isolated and cloned. CB1 is predominantly expressed in the
central nervous system and has been also detected in the testis,
spleen cells and leukocytes [13, 14]. CB2, mainly expressed by cells
of the immune system, is also present on microglial cells [12–14].
A recent report has suggested that the endocannabinoid sys-
tem could play a role in lung function. In fact, anandamide, an
endocannabinoid agonist, is produced in lung tissue and CB1
receptors are expressed on axon terminals of nerve fibres in rat
bronchiolar smooth muscle [15]. In a rodent model of bronchial
hyper-responsiveness, anandamide exerted opposite effects: it
strongly inhibited bronchospasm and cough evoked by capsaicin,
whereas it caused bronchospasm when the constricting tone
exerted by the vagus nerve was removed [15]. Therefore, the acti-
vation of CB1 receptors by locally released anandamide could par-
ticipate in the control of bronchial contractility. The existence of an
intrinsic endocannabinoid-mediated control of airway function
may open new perspectives for the development of new anti-
 tussive and anti-asthmatic agents.
Recently, selective agonists and antagonists for the CB1 and
CB2 receptors have been made available, thus offering a suitable
pharmacological tool to better understand the role of the cannabi-
noid receptors in lung physiopathology. The aim of this study was
to investigate the role of CB1 and CB2 receptors on allergic asthma-
like reaction in a well-established in vivo model of ovalbumin (OV)-
sensitized guinea pigs [16, 17]. We used the cannabinoid receptor
agonist CP55, 940 (CP) [18], and we tested the ability of the spe-
cific CB2 receptor antagonist SR144528 (SR) [19] and CB1 recep-
tor antagonist AM251 (AM) [20] to interfere with the effects of CP.
Materials and methods
Animals
Male adult albino guinea pigs were quarantined for 7 days at 22–24°C on
a 12 hrs light, 12 hrs dark cycle before use. The experimental protocol was
basically the same used previously for similar purposes [16, 17]. It com-
plied with the recommendations of the European Economic Community
(86/609/CEE) for the care and use of laboratory animals and was approved
by the animal care committee of the University of Florence (Florence, Italy).
At the end of the treatments, the animals weighed 350–400 g.
Treatments
Group 1. Eight guinea pigs were injected with saline (5 ml/kg i.p., plus 5
ml/kg s.c.). Two weeks later, they were treated with an aerosol of ovalbu-
min (OV; Fluka, Buchs, Switzerland) suspended in PBS (5 mg/ml). They are
referred to as naive controls.
Other guinea pigs were sensitized with OV (100 mg/kg i.p., plus 100
mg/kg s.c.), dissolved in water to a concentration of 20 mg/ml. Two weeks
later, they were challenged with an OV aerosol (5 mg/ml saline) to verify that
sensitization had occurred. The animals were withdrawn from antigen expo-
sure at the first sign of respiratory abnormality. The animals that developed
a clear-cut immediate asthma-like reaction to the inhaled antigen are referred
to as sensitized animals. After 4–8 days, they were randomly divided in four
further groups, eight animals each, and treated as indicated below.
Group 2. Treatment with an i.p. injection of 1 ml Phosphate buffered
Saline (PBS). Three hours later, the animals underwent challenge with OV
aerosol, as described below. They are referred to as OV-challenged animals.
Group 3. Treatment with an i.p. injection of CP55,940 (CP; Tocris
Cookson, Bristol, UK; 0.4 mg/kg b.wt.), dissolved in 1 ml PBS. Three hours
later, the animals underwent challenge with OV aerosol, as described
below. They are referred to as CP-treated animals.
Group 4. Treatment with an i.p. injection of the CB2 antagonist
SR144528 (SR; kindly provided by Sanofi Recherche, Montpellier, France;
10 mg/kg b.wt.), dissolved in 1 ml PBS. One hour later the animals were
treated with an i.p. injection of 1 ml CP (0.4 mg/kg b.wt.), and after further
3 hours, underwent challenge with OV aerosol. They are referred to as
SR+CP-treated animals
Group 5. Treatment with an i.p. injection of the CB1 antagonist AM251
(AM; Tocris Cookson, Bristol, UK; 10 mg/kg b.wt.), dissolved in 1 ml PBS.
One hour later the animals were treated with an i.p. injection of 1 ml CP 
(0.4 mg/kg b.wt.), and after further 3 hrs, underwent challenge with OV
aerosol. They are referred to as AM+CP-treated animals
Group 6. Treatment with an i.p. injection of SR (10 mg/kg b.wt.) plus
AM (10 mg/kg b.wt.), dissolved in 1 ml PBS. One hour later the animals
were treated with CP (0.4 mg/kg b.wt.), and after further 3 hrs, underwent
challenge with OV aerosol. They are referred to as SR+AM+CP-treated 
animals.
The above dose of CP was selected basing on preliminary observations
that it did not cause substantial hypomotility of the treated animals. The
doses of AM and SR were chosen by comparison with that of CP, based on
their receptor affinity [19, 20].
Evaluation of respiratory activity
The guinea pigs of all the groups were placed in a whole body respiratory
chamber, as described previously [16, 17]. The changes in inner pressure
induced by breathing were monitored with a high sensitivity pressure
transducer connected with a polygraph (Battaglia-Rangoni, Comerio, Italy).
Upon stabilization of the breath pattern, the guinea pigs were challenged
with an OV aerosol (5 mg/ml in water) for 10 sec. Changes in the respira-
tory activity of the animals subjected to the different treatments were
recorded for 10 min. after OV aerosolization. Evaluation of the following
parameters was achieved: (i) latency time (sec.) for the appearance of res-
piratory abnormalities after the onset of aerosolization; (ii) cough severity
score, assessed as the product of cough frequency (cough strokes/min.)
and mean cough amplitude (in mmHg); (iii) latency time (sec.) for the
appearance of dyspnea, recognized in breath recordings as a series of
irregular breaths of abnormally elevated or reduced amplitude compared
with the basal breath. Any motion- and sneezing-related changes in the
inner pressure of the body chamber were visually detected and discarded.
At the end of the test, the guinea pigs were killed by lethal i.p. injections
of sodium thiopenthal (Abbott, Latina, Italy). Bronchoalveolar lavage (BAL)
was carried out by cannulation of the trachea and instillation of 3 ml of
PBS, pH 7.4. BAL fluid was then centrifuged at 1,100 g for 30 min. The cell-
free supernatant was collected, its volume measured and frozen at 70°C
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until needed. The thorax was then opened allowing for the gross appear-
ance of lungs to be examined. Tissue specimens from the right lung were
excised and processed for further analyses, as described below.
Histological and morphometric analyses
Tissue samples, two from each animal (one from the middle lobe and one from
the lower lobe), were fixed by immersion in Mota fluid and embedded in paraf-
fin. This fixative solution allows a rapid infiltration of the tissue, with only min-
imal artifactual shrinking, thus providing a tissue morphology which is repre-
sentative of the lung features in vivo. For each animal, sections 5 m thick cut
from the two different lung samples were stained with haematoxylin and eosin
or with Astra blue (Fluka, Buchs, Switzerland) to reveal mast cell granules.
A first series of determinations was carried out on haematoxylin and
eosin-stained sections to evaluate the surface area of alveolar aerial spaces,
examined with a 10 objective. Five randomly chosen microscopical fields
per animal were analysed. At the chosen magnification, each field corre-
sponded to a tissue area of 570,224 m2. The same tissue sections were
used to evaluate the surface area of bronchial lumina, selected by: (i) histo-
logical appearance of small-sized, muscular bronchi; (ii) transverse or slight-
ly oblique cross-section. In each guinea pig, measurements were carried out
on 4–6 randomly chosen bronchial profiles, examined with a 20 objective.
For both alveolar and bronchial luminal areas, digital images of the micro-
scopical fields were taken. On these images, surface area measurements
were carried out using the Scion Image  4.0.2 image analysis program
(Scion Corp., Frederick, MD) upon appropriate thresholding to include only
blank, tissue-free aerial spaces. The mean values (± SEM) of alveolar and
bronchial luminal areas were then calculated for each experimental group.
A second series of determinations was carried out on Astra blue-
stained sections to evaluate the optical density of lung mast cells, which is
related to their secretion granule content, as described previously [16, 17].
Digital images of mast cells, taken with a 100 oil immersion objective,
were used for measurement of optical density, carried out on selected mast
cell profiles, using the Scion Image  4.0.2 image analysis program. In
each animal, 30 different mast cells, 15 from each lung sample, were
analysed and the mean optical density value (± SEM) was then calculated
for the entire experimental group.
Immunohistochemisty for eosinophilic major
basic protein (eMBP)
Lung tissue sections were treated with 0.3% (v/v) H2O2 in 60% (v/v)
methanol to quench endogenous peroxidase, permeabilized with 0.1 % (w/v)
Triton X 100 in PBS for 20 min. and incubated overnight with human mono-
clonal anti-eMBP (clone BMK13, Chemicon, Temecula, CA; working dilution:
1:50 in PBS). Immune reaction was revealed by indirect immunoperoxidase
method (Vectastain Elite kit, Vector, Burlingame, CA, USA), using 3, 3´-
diaminobenzidine as chromogen. As negative controls, sections incubated
with only the primary or the secondary antisera were used. In each guinea
pig, the number of eMBP-positive eosinophils was counted in 10 randomly
chosen microscopical fields at a 200 final magnification (test area: 72,346
m2). Values obtained from two different observers were averaged.
Evaluation of myeloperoxidase activity
Myeloperoxidase activity, a marker for leukocyte accumulation in tissues, was
evaluated according to Bradley et al. [21] Briefly; frozen lung tissue fragments
weighing approximately 100 mg were thawed and homogenized in 1.5 ml of
50 mmol/l potassium phosphate buffer, pH 6. One ml of the homogenate was
centrifuged at 10,000 g for 10 min. and the pellet suspended in 1 ml of
potassium phosphate buffer (50 mmol/l), pH 6, containing 0.5% hexade-
cyltrimethylammonium bromide (Sigma, Milan, Italy) to negate the pseudoper-
oxidase activity of haemoglobin and to solubilize membrane-bound myeloper-
oxidase. The suspensions were sonicated on ice and centrifuged at 12,000 g
for 10 min. Myeloperoxidase activity was determined in 0.1 ml of the super-
natant, mixed with 2.9 ml of potassium phosphate buffer (50 mmol/l), pH 6,
containing 0.19 mg/ml of o-dianisidine chloride and 0.0005 % H2O2 as a sub-
strate for myeloperoxidase. The absorbance of oxidised o-dianisidine was
determined spectrophotometrically over 2 min. at 460 nm wave length The val-
ues of tissue myeloperoxidase activity were obtained by comparison with stan-
dard concentrations of o-dianisidine and excess H2O2 and expressed as
mU/mg of proteins, these latter determined with the Bradford method [22].
Determination of 8-hydroxy-2´-deoxyguanosine
(8-OHdG)
8-OHdG was measured as a marker of free radical-induced DNA damage,
according to Lodovici et al. [23]. DNA was isolated from frozen tissue samples,
which were thawed, homogenized in 1 ml of 10 mM phosphate buffered saline,
pH 7.4, sonicated on ice for 1 min, added with 1 ml of 10 mM Tris-HCl buffer,
pH 8, containing 10 mM ethylenediaminetetraacetic acid (EDTA), 10 mM NaCl,
0.5 % SDS, and incubated for 1 hr at 37°C with 20 g/ml RNAse (Sigma).
Then, the samples were incubated overnight at 37°C under argon, in the pres-
ence of 100 g/ml proteinase K (Sigma). The mixture was then extracted with
chloroform/isoamyl alcohol (10:2 v/v) and DNA precipitated from the aqueous
phase with 10 M ammonium acetate, dissolved in 200 l of 20 mM acetate
buffer, pH 5.3 and denatured at 90°C for 3 min. The extract was then incubat-
ed for 1 hr at 37°C with 10 IU of P1 nuclease and 5 IU of alkaline phosphatase
in 0.4 M phosphate buffer, pH 8.8. The mixture was filtered by an Amicon
Micropure-EZ filter (Amicon, MA, USA) and 50 l of each sample were used
for 8-hydroxy-2´-deoxyguanosine (8-OHdG) determination using a Bioxytech
EIA kit (Oxis, Portland, OR, USA), following the instructions provided by the
manufacturer. The protein concentration was determined as described above
and the values are expressed as ng of 8-OHdG/mg of protein.
Tumour necrosis factor- (TNF) 
and prostaglandin D2 (PGD2) 
determination in BAL fluid
The release of TNF and PGD2 into the BAL fluid were measured using
commercial enzyme immunoassay (EIA) kits (Cayman Chemical, Ann Arbor,
MI, USA), following the manufacturer’s instructions. Protein content of the
BAL samples taken from animals belonging to the different experimental
groups, measured by the Bradford method, was substantially similar. Thus,
the results have been expressed as ng/ml of BAL fluid.
Determination of cyclic nucleotides
Lung tissue samples were homogenized in the presence of 3-isobutyl- 
1-methylxanthine (IBMX, 50 µm) to inhibit phosphodiesterase activity. 
The levels of cGMP and cAMP were measured in the aqueous phase of the
tissue homogenates, extracted in 10% trichloroacetic acid added with 
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0.5 mM tri-n-octylamine in 1,1,2-trichlorotrifluoroethane, using commercial
radioimmunoassay kits (Amersham, Bucks, UK). Determinations were per-
formed in duplicate. Values are expressed as fmol cGMP and nmol cAMP
per min. per mg of proteins, the latter determined as described above. 
Determination of cannabinoid 
receptors by Western blotting
Lung tissue samples were homogenized in cold lysis buffer (20 mM Tris-
HCl, 0.15 M NaCl, 5 mM EDTA, 100 mM phenylmethylsulfonyl fluoride, 2.5
mM leupeptin, 2.5 mM aprotinin). Homogenates were centrifugated at
10,000  g for 20 min. at 4°C and the supernatant was collected. Proteins
were quantified using Bio-Rad Protein Assay reagent (Hercules, CA, USA).
Then, samples containing 75 g of proteins each were loaded on a 10%
SDS-PAGE gel, resolved by electrophoresis and blotted onto a polyvinyli-
dene difluoride membranes (Millipore, Bedford, MA, USA). After treatment
with blocking buffer (5% dry milk and 0.05% Tween 20 in PBS: PBS-T) for
1 hr at room temperature, the membranes were incubated overnight with
primary antibodies against CB1 and CB2 receptors (1:250; Alexis
Biochemicals, San Diego, CA, USA) in PBS-T. Then, the membranes were
washed and incubated with horseradish peroxidase-conjugated secondary
antibodies (1:5000; Pierce, Rockford, II, USA). Immunoreactivity was
detected by an enhanced-chemiluminescence assay (Supersignal, Pierce,
Rockford, Il, USA). As controls, membranes incubated with antibodies
against -tubulin as invariant protein (1:10,000 in PBS-T) were used. 
Statistical analysis
Statistical comparison of differences between the experimental groups was
carried out using one-way ANOVA test followed by Student–Newman–Keuls
multiple comparison test. P < 0.05 was considered significant. Calculations
were done using a GraphPad Prism 4.0 statistical program (GraphPad
Software, San Diego, CA, USA).
Results
CP reduces OV-induced respiratory abnormalities
The values of the respiratory parameters assayed are reported in
Fig. 1A–C. There were no substantial abnormalities in the naive
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Fig. 1 Occurrence of respiratory abnormal-
ities in guinea pigs of the different experi-
mental groups. (A) latency time (sec.) for
the onset of cough; (B) cough severity; (C)
latency time (sec.) for the appearance of
dyspnea. Compared with the sensitized,
ovalbumin (OV)-challenged animals (group
2), a 3-hrs treatment with the CB1/CB2
receptor agonist CP of the sensitized
guinea pigs before OV challenge (group 3)
resulted in a statistically significant reduc-
tion of the respiratory abnormalities. Pre-
treatment of the sensitized guinea pigs
with the CB1 receptor antagonist SR
(SR+CP, group 4) or the CB2 receptor
antagonist AM (AM+CP, group 5) or both
(SR+AM+CP, group 6) before CP adminis-
tration markedly reverted the protection
afforded by CP. Significance of differences
(one-way ANOVA; each group: n = 8): 
# P < 0.001 versus naive; *** P < 0.001
versus OV; + P < 0.05 and +++ P < 0.001 
versus CP.
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control guinea pigs after inhalation of OV aerosol (group 1),
apart from sporadic cough strokes arising about 2 min. after the
onset of the aerosol. Challenge of PBS-pre-treated, sensitized
guinea pigs with the OV aerosol (group 2) resulted in striking
abnormalities of the respiratory pattern, consisting of a signifi-
cant reduction of the latency time for the onset of cough and
dyspnea and a significant increase in the severity of cough.
Conversely, a 3-hr pre-treatment with CP of the sensitized guinea
pigs before OV challenge (group 3) resulted in a marked, statis-
tically significant reduction of the respiratory abnormalities com-
pared with the OV-challenged animals of group 2. In particular,
the latency for cough and dyspnea increased and the cough
severity decreased. Pre-treatment of the sensitized guinea pigs
with the CB2 antagonist SR (group 4) and the CB1 antagonist AM
(group 5) before CP administration reverted the protection
afforded by CP; in this context, SR was more effective than AM.
The respiratory parameters of the animals treated with both the
antagonists (group 6) were similar to those of the animals treat-
ed with SR (group 4).
CP reduces OV-induced lung
histopathological changes
Compared with the naive controls (group 1), macroscopic examina-
tion of the lungs showed prominent changes in the OV-challenged
guinea pigs (group 2). The pulmonary lobes were swollen because
of air entrapment and focal subpleural hemorrhagic foci were
observed. Sectioning of trachea or of main bronchi did not cause
lung deflation, thus indicating that peripheral airway obstruction had
occurred. Lung inflation and subpleural haemorrhage were not
found in the CP-treated guinea pigs (group 3), whereas they were
present in most of the animals given SR, AM or both before CP
(group 4, 5 and 6). By light microscopy (Fig. 2), the lung parenchy-
ma of naive guinea pigs (group 1) had a normal appearance: intra-
pulmonary bronchi showed open lumina and respiratory air spaces
were mostly small-sized (Fig. 2A). Conversely, the lungs from the
OV-challenged guinea pigs (group 2) mostly showed a reduction of
the lumen of intrapulmonary bronchi, with long mucosal folds
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Fig. 2 Representative light micrographs of lung tissue from naive guinea pigs given OV aerosol (A; group 1), sensitized guinea pigs challenged with
OV aerosol (B; group 2), sensitized guinea pigs treated with the CB1/CB2 receptor agonist CP before OV challenge (C; group 3), sensitized guinea pigs
pre-treated with CP in combination with the CB1 receptor antagonist SR (D; group 4), the CB2 receptor antagonist AM (E; group 5) or both (F; group
6). Compared with the animals of group 1, those of group 2 show reduction of bronchiolar lumen and dilation of the respiratory air spaces. These
alterations are not evident in the CP-treated guinea pigs of group 3, but persist in the animals given SR, AM or both 3 hours before CP (groups 4, 5
and 6, respectively). Haematoxylin and eosin. Bars = 100 m.
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expanding into the lumen and markedly dilated respiratory air
spaces (Fig. 2B). In the CP-treated guinea pigs (group 3), the histo-
logical lung abnormalities were nearly abrogated. In fact, the intra-
pulmonary bronchi usually showed no appreciable signs of con-
striction, and most respiratory air spaces were not dilated (Fig. 2C).
In the guinea pigs pre-treated with SR, AM or both the antagonists
before CP (groups 4, 5 and 6), the histological features were quite
similar to those of the OV-challenged animals (Fig. 2D–F).
The visual observations were objectified by morphometric
analysis (Fig. 3A and B). Compared with the naive guinea pigs
of group 1, the OV-challenged guinea pigs (group 2) showed a
significant increase in the mean surface area of alveolar air
spaces and a significant decrease in the mean surface area of
bronchiolar lumina. In the CP-treated guinea pigs (group 3) the
mean surface area of alveolar air spaces nearly returned to the
control values and the mean surface area of bronchiolar lumina
was significantly increased compared to the OV-challenged ani-
mals. With respect to the CP-treated group, pre-treatment with
SR, or AM, or both the antagonists significantly prevented the
CP-induced reduction of the mean surface area of alveolar air
spaces but had little effects on the mean surface area of bron-
chiolar lumina.
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Fig. 3 Surface area of alveolar air spaces (A) and small-sized bronchial lumina (B) in the lungs of guinea pigs from the different experimental groups.
Compared to the OV-challenged, untreated animals (group 2) in the guinea pigs treated with the CB1/CB2 receptor agonist CP (group 3) the mean sur-
face area of alveolar air spaces nearly returned to the control values and the mean surface area of bronchiolar lumina was significantly increased. With
respect to the CP-treated group, pre-treatment of the sensitized guinea pigs with the CB1 receptor antagonist SR (SR+CP, group 4) or the CB2 recep-
tor antagonist AM (AM+CP, group 5) or both (SR+AM+CP, group 6) before CP administration significantly prevented the reduction of the mean 
surface area of alveolar air spaces but not the increase of the mean surface area of bronchiolar lumina. Significance of differences (one-way ANOVA): 
# P < 0.001 versus naive; *** P < 0.001 and *P < 0.05 versus OV; +++ P < 0.001 versus CP.
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CP reduces OV-induced mast cell granule release
Lung mast cells from the OV-challenged guinea pigs (group 2)
underwent a marked decrease in Astra blue staining intensity,
which depends on secretion granule content, as compared with
those from the naive controls (group 1), thus indicating that gran-
ule discharge has occurred (Fig. 4A and B). In the CP-treated
guinea pigs (group 3), the mast cell staining intensity was
markedly increased in respect to the OV-challenged animals
(group 2), attaining values similar to those of the controls (Fig. 4C).
As compared with the animals of group 3, mast cell staining inten-
sity was slightly decreased in the guinea pigs pre-treated with SR
(group 4), or AM (group 5), or both the antagonists (group 6) 
(Fig. 4D–F). Computer-aided densitometry confirmed the visual
observations (Fig. 4G). Compared with the naive controls (group
1), the optical density of Astra blue-stained mast cells was signif-
icantly reduced in OV-challenged guinea pigs (group 2), but not in
the CP-treated guinea pigs (group 3). As compared with the latter
animals, mast cell optical density was decreased, but not signifi-
cantly, in the guinea pigs pre-treated with SR (group 4), whereas
the decrease reached statistical significance in the guinea pigs
pre-treated with AM (group 5) and in those pre-treated with both
the antagonists (group 6).
CP reduces OV-induced lung leukocyte infiltration
Myeloperoxidase activity (Fig. 5), a marker of leukocyte infiltration
into inflamed tissues, as well as eMBP-positive eosinophils (Fig.
6) were assayed in the different experimental groups. Both param-
eters markedly and significantly increased in the OV-challenged
guinea pigs (group 2) compared with the controls (group 1). In
the CP-treated guinea pigs (group 3), myeloperoxidase activity
and the number of eMBP-positive eosinophils were significantly
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Fig. 4 Representative images of Astra
Blue-stained mast cells from naive
guinea pigs given OV aerosol (A, group
1), sensitized guinea pigs challenged
with OV aerosol (B, group 2), sensitized
guinea pigs treated with the CB1/CB2
receptor agonist CP before OV challenge
(C, group 3), sensitized guinea pigs pre-
treated with CP in combination with the
CB1 receptor antagonist SR (D, group
4), the CB2 receptor antagonist AM 
(E, group 5) or both (F, group 6).
Compared with the animals of group 1,
those of group 2 show a clear-cut reduc-
tion of mast cell staining intensity.
These alterations are not evident in the
CP-treated guinea pigs of group 3, but
persist in the animals given SR, AM or
both 3 hrs before CP (groups 4, 5 and 6,
respectively). Astra blue staining. Bars =
10 m. The visual observations are
confirmed and objectified by computer-
aided densitometry on selected mast
cell profiles (G). Significance of differ-
ences (one-way ANOVA): # P < 0.001 
versus naive; ** P < 0.01 versus OV; 
+ P < 0.05 and +++ P < 0.001 versus CP.
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decreased compared with the animals of group 2. Pre-treatment
with SR significantly prevented the reduction of myeloperoxidase
activity and the number of eMBP-positive eosinophils due to CP,
while pre-treatment with AM only prevented the reduction of the
number of eMBP-positive eosinophils. Myeloperoxidase activity and
the number of eMBP-positive eosinophils evaluated in the animals
pre-treated with both the antagonists (group 6) were similar to
those of animals pre-treated with SR alone (group 4).
CP reduces OV-induced 8-OHdG production
Tissue levels of 8-OHdG (Fig. 7), a marker of free radical-induced
DNA damage, significantly increased in the OV-challenged guinea
pigs (group 2) compared with the controls (group 1). In the CP-
treated guinea pigs (group 3), the levels of 8-OHdG were signifi-
cantly decreased compared with the OV-challenged animals of
group 2. Pre-treatment with SR, but not with AM, significantly pre-
vented the reduction of 8-OHdG. The levels of 8-OHdG evaluated
in the animals treated with both the antagonists (group 6) were
slightly increased as compared with the animals pre-treated with
SR alone (group 4).
CP reduces OV-induced release 
of TNF and PGD2 in BAL fluid
The inflammatory cytokine TNF (Fig. 8A) and PGD2 (Fig. 8B)
were markedly increased in the BAL fluid from OV-challenged
guinea pigs (group 2) compared with the controls (group 1). In
the CP-treated guinea pigs, the values of TNF and PGD2 in BAL
fluid were significantly lower than in the animals of group 2. Pre-
treatment with SR or AM prevented the CP-induced decrease of
TNF and PGD2 levels in BAL fluid, with SR being the most effec-
tive. Pre-treatment with both the antagonists (group 6) caused
similar effects as SR alone.
CP reduces OV-induced increase of cAMP levels
As CB1 and CB2 receptors are G protein-associated, cyclic
nucleotide-operating receptors, we evaluated the levels of cAMP
and cGMP in lung tissue extracts. Cyclic AMP levels (Fig. 9A) in
lung tissue were similar in the samples from the OV-challenged
animals (group 2) and the controls (group 1). In the CP-treated
guinea pigs (group 3), the values of cAMP were significantly lower
than in the previous groups, while in the animals pre-treated with
the antagonists, given alone or together (groups 4–6), the cAMP
values were similar to those of the control (group 1) and OV-chal-
lenged animals (group 2). On the other hand, cGMP levels did not
change among the experimental groups (Fig. 9B).
CP treatment does not modify the expression of
cannabinoid receptor proteins
Western blot analysis showed that both CB1 and CB2 receptors are
expressed in guinea pig lung tissue and that neither the treatment
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Fig. 5 Lung tissue myeloperoxidase (MPO) activity in the guinea pigs from the different experimental groups. In the guinea pigs treated with the
CB1/CB2 receptor agonist CP (group 3) MPO activity is significantly decreased compared with the OV-challenged untreated guinea pigs (group 2).  
Pre-treatment with the CB1 receptor antagonist SR (SR+CP, group 4) or SR and the CB2 receptor antagonist AM (SR+AM+CP, group 6) before CP
administration prevented the reduction of MPO activity, while pre-treatment with AM alone (AM+CP, group 5) had no effects. Significance of differ-
ences (one-way ANOVA): # P < 0.001 versus naive; *** P < 0.001 versus OV; +++ P < 0.001 versus CP.
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Fig. 6 Eosinophils positive for eMBP in the lung tissue from naive guinea pigs given OV aerosol (A, group 1), sensitized guinea pigs challenged with
OV aerosol (B, group 2), sensitized guinea pigs treated with the CB1/CB2 receptor agonist CP before OV challenge (C, group 3), sensitized guinea
pigs pre-treated with CP in combination with the CB1 receptor antagonist SR (D, group 4), the CB2 receptor antagonist AM (E, group 5) or both 
(F, group 6). Pre-treatment with CP (group 3) reduces the amount of eMBP-positive eosinophils compared with the untreated, OV-challenged guinea
pigs (group 2). Pre-treatment with the CB1 receptor antagonist SR (SR+CP, group 4), the CB2 receptor antagonist (AM+CP, group 5) or both
(SR+AM+CP, group 6) before CP administration prevents the reduction eMBP-positive eosinophils. Morphometrical analysis (G) confirmed the
 visual observations. Significance of differences (one-way ANOVA): # P < 0.001 versus naive; *** P < 0.001 versus OV; + P < 0.05 and +++ P < 0.001
versus CP.
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Fig. 7 Lung tissue levels of 8-hydroxy-2´-deoxyguanosine (8-OHdG) in the guinea pigs from the different experimental groups. In the guinea pigs treat-
ed with the CB1/CB2 receptor agonist CP (group 3), the levels of 8-OHdG were significantly decreased compared with the untreated, OV-challenged
animals (group 2). Pre-treatment with the CB1 receptor antagonist SR (SR+CP, group 4) or SR and the CB2 receptor antagonist AM (SR+AM+CP, group
6) before CP administration prevented the reduction of 8-OHdG. Significance of differences (one-way ANOVA): # P < 0.001 versus naive; 
***P < 0.001 versus OV; +++ P < 0.001 versus CP.
Fig. 8 Levels of tumour necrosis factor-
TNF- (A) and PGD2 (B) in BAL fluid of
guinea pigs from the different experimental
groups. In the guinea pigs treated with the
CB1/CB2 receptor agonist CP (group 3), the
values of TNF and PGD2 were significantly
lower than in the untreated, OV-challenged
animals (group 2). Pre-treatment with the
CB1 receptor antagonist SR (SR+CP, group 4)
or the CB2 receptor antagonist AM (AM+CP,
group 5) or both (SR+AM+CP, group 6)
before CP administration prevented the CP-
induced decrease of TNF and PGD2 levels.
Significance of differences (one-way ANOVA): 
# P < 0.001 versus naive; ***P < 0.001
versus OV; + P < 0.05 and +++ P < 0.001
versus CP.
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with CP nor pre-treatment with the noted antagonists resulted in
any modification in the receptor protein expression (Fig. 10).
Discussion
This study provides evidence that the cannabinoid receptor ago-
nist CP55,940 (CP) is able to counteract the allergen-induced
functional, biochemical and histopathological lung changes in a
guinea pig model of allergic asthma-like reaction to OV aerosol.
Systemic pre-treatment of OV-sensitized guinea pigs with CP 3 hrs
before OV challenge caused a significant reduction of the occur-
rence of respiratory abnormalities (cough and dyspnea), bronchial
lumen restriction, alveolar hyperinflation, leukocyte and
eosinophilic infiltration, mast cell activation and free radical-
induced DNA injury compared with the vehicle-treated OV-chal-
lenged controls. Moreover, a drop of the inflammation-related
molecules TNF and PGD2 was observed in BAL fluid from the
animals treated with CP. A schematic diagram summarizing the
data and highlighting the hypotheses on how CP may work in the
current asthmatic model is given in Fig. 11. Briefly, we suggest
that CP may promote bronchodilation by stimulation of CB1 recep-
tors on bronchial smooth muscle cells and nerve endings and, in
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Fig. 9 Lung tissue levels of cAMP (A) and
cGMP (B) in the guinea pigs from the differ-
ent experimental groups. In the guinea pigs
treated with the CB1/CB2 receptor agonist CP
(group 3), the values of cAMP were signifi-
cantly lower than in the untreated, OV-chal-
lenged animals (group 2) and in the naive
animals (group 1). Pre-treatment with the
CB1 receptor antagonist SR (SR+CP, group
4) or the CB2 receptor antagonist AM
(AM+CP, group 5) or both (SR+AM+CP,
group 6) before CP administration prevented
this decrease. The levels of cGMP were not
different among the experimental groups.
Significance of differences (one-way ANOVA): 
***P < 0.001 versus OV; +++ P < 0.001
versus CP.
Fig. 10 Western blot analysis of CB1 and CB2
cannabinoid receptors in lung tissue of the
guinea pigs from the different experimental
groups. The treatment with the CB1/CB2
receptor agonist CP (group 3), alone or in
combination with the CB1 receptor antago-
nist SR (SR+CP, group 4), the CB2 receptor
antagonist AM (AM+CP, group 5) or both
(SR+AM+CP, group 6) did not cause any
modification in the receptor protein expres-
sion when compared to the naive (group 1)
or the untreated, OV-challenged animals
(group 2).
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the meantime, exert inhibitory effects on lung tissue mast cells
and eosinophils recruited by allergen challenge by stimulation of
CB2 receptors.
The actions of cannabis on airway functions have been among
the effects first explored for potential therapeutic use [24].
Smoked marijuana and ingested 9-tetrahydrocannabinol (THC)
were found to decrease airway resistance and to increase airway
conductance both in healthy and asthmatic subjects [3]. However,
even though these findings may suggest that THC could be thera-
peutically used as a bronchodilator in asthma, it should be under-
lined that smoke-borne delivery of cannabinoids to asthmatic
patients is contraindicated because of the noxious gaseous and
particulate substances in smoke, whose long-term effects include
chronic airway irritation and tumourigenesis [24]. Moreover, oral
THC is not suitable for therapeutic use in asthma due to its
adverse toxic effects on the central nervous system and positive
cardiac chronotropism, opposed to its modest bronchodilator
properties [4, 25].
The mechanisms of cannabinoid-induced bronchodilation have
been recently studied but not yet completely understood [15]. In
the present in vivo study, we have shown that the cannabinoid
agonist CP has marked anti-inflammatory effects. Our study also
confirms that both CB1 and CB2 receptors are involved in lung
response to CP, as indicated by the increase of the lung tissue lev-
els of cAMP, the second messenger of CB receptor activation,
upon CP administration to the guinea pigs. Western blot analysis
demonstrated that CP causes no modification of the receptor pro-
tein expression.
Mast cells are known as key players during the early phase of
allergy, since allergen-induced cross-linking of their high affinity
IgE receptors culminates in massive degranulation and release of
pro-inflammatory mediators, such as histamine, TNF and PGD2,
with potent and rapid effects on blood vessels and bronchial
smooth muscle cells. This explains the majority of symptoms
experienced by asthmatics during the early phase [26]. Our find-
ings indicate that the observed decrease of mast cell granule
release afforded by CP in OV-challenged animals was CB1/CB2
mediated. Moreover, both CB1 and CB2 antagonists were able to
blunt the inhibitory effect of CP on the release of TNF and PGD2
in BAL fluid, demonstrating that both receptors are involved. In
this context, the localization of CB1 receptors on nerve endings in
close proximity to airway smooth muscle cells [15] could explain
not only bronchodilation but also the anti-inflammatory effects of
CP. In fact, mast cells have been found in close contact with nerve
fibres [27], suggesting a neural control on mast cell function
[28–30]. The influence between nerves and mast cells is recipro-
cal: neurons change their firing rate upon mast cell degranulation
[29], and mast cells may activate upon neural stimulation [30]. A
feedback has been also suggested for mast cells and non-myeli-
nated sensory C-fibres [31], the major vagal afferents to the air-
ways [32], which have been involved in lung vascular and
bronchial changes caused by allergy [33] and by inhalation of
chemical irritants and air pollutants [34]. Our data suggest that CP
may directly reduce the activation of mast cells via their CB2
receptors, as we previously demonstrated in vitro [6], and also
indirectly via the CB1 receptors located on nerve endings distrib-
uting to the bronchial smooth muscle coat [15].
The present study also shows that CB2 receptors are likely
involved in the decrease in myeloperoxidase (MPO) activity and
eMBP-positive eosinophils induced by CP. This indicates that CP
exerts its anti-inflammatory activity mainly through CB2 receptors,
in keeping with our previous results [6, 35]. As activated leuko-
cytes are the main source for oxidizing free radicals, it appears
that inhibition by CP of CB2-dependent leukocyte recruitment into
the allergen-challenged lung tissue is directly related to the reduc-
tion of oxidative DNA damage, as indicated by the reduced levels
of 8OHdG. Multiple mechanisms have been demonstrated for
cannabinoids, including receptor-dependent and -independent
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Fig. 11 Schematic diagram summarizing
the effects of the CB1/CB2 receptor agonist
CP55,940 in the current model of allergic
asthma-like reaction. CB1, CB2, cannabinoid
receptors 1 and 2; MPO, myeloperoxidase;
ROS, reactive oxygen species.
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effects [10, 36]. Among the latter ones, the indirect, antioxidant
effects of cannabinoids may turn out very useful in asthma, con-
sidering that increased levels of oxygen-derived free radicals and
high-energy oxidants produced by inflammatory and epithelial
cells in the airways are deemed important pathogenic mediators of
asthma [37, 38].
In conclusion, this study provides background to the concept
that novel non-psychoactive cannabinoid analogues with
 bronchodilator and anti-inflammatory activity could find a thera-
peutical use as adjuncts in the treatment of allergic asthma, espe-
cially as preventative agents which could blunt the severity of asth-
matic attacks and in patients who are at risk for adverse side effects
by the major anti-asthmatic drugs. In particular, cannabinoid deriv-
atives selectively targeting CB2 receptors appear as the most prom-
ising drugs, as they should be free of central side effects. However,
based on the putative role of CB1 receptors shown by the current
study, CB1 agonists could also be worthy of attention. Of note,
vapourizing devices are now commercially available which could be
used for safe cannabinoid delivery [39]. Such tools could meet the
requirement for high lung cannabinoid uptake, while avoiding the
respiratory disadvantage of smoking and reducing the risk for
adverse cardiovascular and neural side effects.
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